0
Diffuse Lung Disease |

The Attenuating Effect of Erythropoietin (EPO) on the Expression of Myeloperoxidase (MPO) in Bleomycin (BLM)-Induced Pulmonary Fibrosis (PF) in Rats

Drosos Tsavlis, PhD; Anna Tzoumaka, MD; Georgia Kokaraki, PhD; Kokona kouzi-Koliakos, PhD; Anastasia Tektonidou, NHA; Evangelia Spandou, PhD
Author and Funding Information

Aristotle University, Thessaloniki, Greece


Chest. 2013;144(4_MeetingAbstracts):462A. doi:10.1378/chest.1702547
Text Size: A A A
Published online

Abstract

SESSION TITLE: Cytokines/Cellular Interactions Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: The enzyme myeloperoxidase is very well known to participate in the fibrotic pathway with inflammatory and apoptotic actions. EPO is a multiple functional cytokine with anti-oxidative, anti-inflammatory and anti-apoptotic properties. Aim of this study was to investigate the role of EPO on the expression of MPO in bleomycin-induced pulmonary fibrosis in rats.

METHODS: Fifty Wistar rats (average weight 300gr) were divided into five groups of 10 animals each. Group 1: control animals, Group 2: intratracheal (i.t) and intraperitoneal (i.p) injection of saline (0.5ml/kg), Group 3: intratracheal injection of BLM hydrochloride (7.5mg/kg), Group 4: intratracheal injection of BLM hydrochloride (7.5mg/kg) followed by intraperitoneal injection of EPO (2000 iu/kg), Group 5: intratracheal injection of saline (0.5ml/kg) followed by intraperitoneal injection of EPO (2000 iu/kg). All rats were sacrified after 14 days. The expression of MPO was immunohistochemically measured and a scale of 4 grades was used to evaluate it (grade A: 0 - 25%, grade B: 25 - 50%, grade C: 50 - 75% and grade D: 75 - 100%) .

RESULTS: In groups 1,2 and 5 (control groups), MPO was expressed mainly in the grade A (80%) and fairly in the grade B (20%). In group 3, MPO was expressed in the high grades C (20%) and D (80%). Finally, in group 4, MPO was expressed only in the low grades A (80%) and B (20%). It is obvious that the expression of the enzyme took place in the high grades for group 3 (BLM group) and in the lower grades for group 4 (BLM+EPO group) (p<0.001 and p<0.005 respectively).

CONCLUSIONS: Administration of EPO after the BLM intratracheal injection (group 4) resulted in significant lower expression of MPO in comparison with the BLM group (group 3). Additional studies are required to clarify the underlying mechanisms of the protective action of EPO on pulmonary fibrosis.

CLINICAL IMPLICATIONS: These findings suggest that EPO may serve as a novel potential target for the therapeutic treatment of PF.

DISCLOSURE: The following authors have nothing to disclose: Drosos Tsavlis, Anna Tzoumaka, Georgia Kokaraki, Kokona kouzi-Koliakos, Anastasia Tektonidou, Evangelia Spandou

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543